Key result
Dual antiplatelet therapy duration after percutaneous coronary interventions requires careful individualization to balance ischemic protection against bleeding risk.
Why the study?
Balancing ischemic protection and bleeding risk requires an individualized approach, making judgment regarding shortened, prolonged, or de-escalated DAPT necessary in select PCI cases.
Does individualized duration of dual antiplatelet therapy (shortened, prolonged, or de-escalated) improve the balance of ischemic and bleeding risks in patients undergoing percutaneous coronary interventions?
Does individualized duration of dual antiplatelet therapy (shortened, prolonged, or de-escalated) improve the balance of ischemic and bleeding risks in patients undergoing percutaneous coronary interventions?
Answers are grounded in this paper and cite their sources.
The duration of DAPT after PCI must be carefully individualized, deviating from standard regimens to shortened, prolonged, or de-escalated strategies based on a patient's specific ischemic and bleeding risk profile.
The antithrombotic therapy is an important part of medical treatment in percutaneous coronary interventions (PCI). The so called dual antiplatelet therapy (DAPT), usually including acetyl salicylic acid (aspirin) plus platelet P2Y12 receptor inhibitors is an important part of that therapy. The careful balance between the protective effect regarding thrombotic/ischemic events and the risk of bleeding is an important task of the attending physician. Apart of the standard dosing regiments, in some of the cases a judgment regarding shortened or prolonged DAPT, as its de-escalation is mandatory. To present the causes and the way of application of that individualized approach in patients with PCI is the aim of this review.
No takes yet. Share an insight, caveat, or question.
Plamen Gatzov (2022) conducted a review in Percutaneous coronary interventions (PCI). Dual antiplatelet therapy (DAPT) was evaluated. Dual antiplatelet therapy duration after percutaneous coronary interventions requires careful individualization to balance ischemic protection against bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: